Marquié G
Atherosclerosis. 1978 Jul;30(3):165-75. doi: 10.1016/0021-9150(78)90043-6.
The aim of the present study was to investigate whether metformin was capable of altering aortic lipid metabolism. Pretreatment of rabbits for 8 days with 120 mg/kg per os metformin reduced by 50--70% the incorporation of a 20 muCi tracer doseof [4(-14)C]cholesterol (given orally 24 h before) into various segments of aorta, plasma, liver, intestine and lung, as compared with control animals. However, as intestinal absorption of cholesterol was also diminished in the same proportion, it was then decided to inject the labelled cholesterol directly into the blood. Under these conditions, metformin induced the same reduction in [4(-14)C]cholesterol specific activity in the aorta, but not in other tissues. Three hours after intravenous injection of a 200 muCi tracer dose of [2(-14)C]-acetate, metformin strongly diminished the radioactivity of total lipids of the aorta, both in fed-rabbits and in rabbits on a 24 h fast, independently of the plasma radioactivity level. The inhibition of acetate incorporation into arterial lipids was observed in all lipid fractions (i.e. free and esterified cholesterol, free fatty acids, phospholipids and especially triglycerides) and the effect persisted unaltered over periods of increasing length after the injection of precursor (1/4, 1/2, 1, 3, 5, 8, 12 h). Metformin also significantly inhibited lipid biosynthesis in the liver and intestine. These properties, added to others previously described, can to a large extent explain the preventive effect of metformin on experimental atherosclerosis.
本研究的目的是调查二甲双胍是否能够改变主动脉脂质代谢。用120mg/kg二甲双胍经口预处理家兔8天,与对照动物相比,[4(-14)C]胆固醇(24小时前经口给予)20μCi示踪剂量掺入主动脉、血浆、肝脏、肠道和肺的各个节段的量减少了50%-70%。然而,由于胆固醇的肠道吸收也以相同比例减少,因此决定将标记的胆固醇直接注入血液。在这些条件下,二甲双胍使主动脉中[4(-14)C]胆固醇的比活性降低,但在其他组织中未降低。静脉注射200μCi示踪剂量的[2(-14)C]-乙酸盐3小时后,二甲双胍显著降低了喂食家兔和禁食24小时家兔主动脉总脂质的放射性,与血浆放射性水平无关。在所有脂质组分(即游离胆固醇和酯化胆固醇、游离脂肪酸、磷脂,尤其是甘油三酯)中均观察到乙酸盐掺入动脉脂质的抑制作用,并且在注射前体后(1/4、1/2、1、3、5、8、12小时),随着时间延长,这种作用持续不变。二甲双胍还显著抑制肝脏和肠道中的脂质生物合成。这些特性,加上先前描述的其他特性,在很大程度上可以解释二甲双胍对实验性动脉粥样硬化的预防作用。